Loading
  • Cortisol Modulation
  • Stories
  • Careers
  • Contact
  • Home
  • About
    • Our Team
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Search
  • Menu Menu
  • Home
  • About
    • Teams
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Stories
  • Careers
  • Contact
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Privacy Notice
  • Terms of Use
  • Site Map

Relacorilant Improved Blood Pressure and Maintained Other Cardiometabolic Improvements in Long-term Study in Patients With Endogenous Hypercortisolism (Cushing Syndrome)

December 13, 2024

Dr. Richard J. Auchus • 2024 • WCIRDC

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2024-12-13 15:10:152024-12-16 13:23:59Relacorilant Improved Blood Pressure and Maintained Other Cardiometabolic Improvements in Long-term Study in Patients With Endogenous Hypercortisolism (Cushing Syndrome)

Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results

December 12, 2024

Araque et al. • 2024 • WCIRDC

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2024-12-12 01:29:492024-12-13 15:13:32Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results

Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study

December 12, 2024

Araque et al. • 2024 • WCIRDC

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2024-12-12 01:27:302024-12-13 15:14:25Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study

Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and cardiovascular disease: Results from CATALYST

December 12, 2024

Fonseca et al. • 2024 • WCIRDC

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2024-12-12 01:24:322024-12-13 15:15:19Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and cardiovascular disease: Results from CATALYST

Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and high blood pressure: Results from CATALYST

December 12, 2024

Handelsman et al. • 2024 • WCIRDC

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2024-12-12 01:00:102024-12-13 15:16:11Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and high blood pressure: Results from CATALYST

Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Results from the First Interim Analysis

November 25, 2024

Badiu et al. • 2024 • AACE MENA 2024 Congress

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2024-11-25 06:00:382024-11-23 00:46:39Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Results from the First Interim Analysis

Relacorilant Maintained Hypertension Improvement in Long-term Follow-up of Patients With Endogenous Hypercortisolism (Cushing Syndrome)

November 25, 2024

Gilis-Januszewska et al. • 2024 • AACE MENA 2024 Congress

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2024-11-25 06:00:052024-11-23 00:40:02Relacorilant Maintained Hypertension Improvement in Long-term Follow-up of Patients With Endogenous Hypercortisolism (Cushing Syndrome)

Rapid Clinical Improvements in a Patient with Difficult-to-Control Type 2 Diabetes by Addressing Underlying Hypercortisolism with Mifepristone

May 14, 2024

2024 • AACE 2024

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2024-05-14 04:44:292024-06-03 18:13:05Rapid Clinical Improvements in a Patient with Difficult-to-Control Type 2 Diabetes by Addressing Underlying Hypercortisolism with Mifepristone

Categories

  • Endocrinology
  • Hypercortisolism (Cushing syndrome)
  • Metabolism
  • Neurology
  • Oncology
  • Other
  • Uncategorized

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube

Scroll to top